Latest Allergy Stories

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. R333 is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus erythematosus (DLE, or lupus of the skin). To...

ROUND ROCK, Texas, Aug. 29, 2012 /PRNewswire/ -- ALK is pleased to announce that it has signed an agreement with HealthTrust Purchasing Group, LP to supply PRE-PEN® (benzylpenicilloyl polylysine injection USP) the only FDA approved skin test for the diagnosis of penicillin allergy, to HealthTrust member facilities, including 1,400 acute care facilities, 10,600 ambulatory surgery centers, physician practices and alternate care sites. HealthTrust will incorporate PRE-PEN®...

OTTAWA, Aug. 29, 2012 /CNW/ - As children head back to the classroom, Health Canada is reminding parents of the importance of allergy awareness when packing lunches for their children. Severe allergic reactions can occur quickly and without warning, and some foods can be life-threatening to allergic children. It is estimated that as many as 1.2 million Canadians may be affected by allergies. Some studies indicate that these numbers are increasing, especially among children....

Hydro Med is pleased to announce that Murray Grossan, M.D., well known Ear Nose Throat specialist, has been commissioned by Basic Health Publications to write a new book on healing for sinus and allergy problems. Mission Hills, CA (PRWEB) August 26, 2012 Dr Grossan is well known for his many innovations in sinus and allergy therapy. His popular sinus books include The Sinus Cure, and Free Yourself from Sinus and Allergy Problems – Permanently. Under the Basic Health Publications...

First microscope to allow visuals to be taken below 40 nanometers of resolution within a cell HOUSTON, Aug. 20, 2012 /PRNewswire-USNewswire/ -- Texas Children's Hospital is the first institution in North America to acquire a Leica Microsystems Gated Stimulation Emission Depletion (G-STED) microscope. The new microscope allows researchers to take never before seen, super-resolution photos below 40 nanometers within a cell and is the only microscope in the world that can acquire images...

CHICAGO, Aug. 17, 2012 /PRNewswire/ -- Do you suffer from hay fever or allergies? Are they one in the same? For those with persistently stuffy, itchy noses, post-nasal drip, and constant sneezing there may be a bigger question. How do I get relief? Chicago allergy expert, Dr. Brian Rotskoff, knows that's the question patients really want answered. Managing the symptoms of hay fever (allergic rhinitis) and nasal congestion, and helping those who suffer from adult sleep apnea,...

MENLO PARK, Calif., Aug. 16, 2012 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded a second grant to Collaborative Drug Discovery, Inc. and SRI International to continue joint development of an information repository and software to identify novel therapeutics for tuberculosis (TB). The Phase II Small Business Technology Transfer Research (STTR) grant will support the next two years of research...

BASKING RIDGE, N.J., Aug. 14, 2012 /PRNewswire/ -- Mylan Specialty L.P., the fully-integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), today announced the EpiPen4Schools(TM) program. This effort offers four free EpiPen(®) or EpiPen Jr(® )(epinephrine) Auto-Injectors upon qualification, which includes having a valid prescription, to public and private kindergarten, elementary, middle and high schools in the U.S. The products will be available in the form of...

SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Meritage Pharma, Inc. announced today that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The trial is being conducted at multiple U.S....

PARIS, Aug. 13, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection...